

No. OQ174841) and to the IPD-IMGT/HLA Database⁵ (Submission No. HWS10065109). The name *HLA-C*07:1058* has been officially assigned by the WHO Nomenclature Committee for Factors of the HLA System⁶ in January 2023. This follows the agreed policy that, subject to the conditions stated in the most recent Nomenclature Report, names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report.

AUTHOR CONTRIBUTIONS

Adèle Dhuyser and Alice Aarnink performed the research. Michaël Pérès, Adèle Dhuyser, Thomas Morel and Alice Aarnink analysed the data. Maël Silva Rodriguez and Adèle Dhuyser wrote the manuscript. Michaël Pérès, Thomas Morel and Alice Aarnink were involved in the critical review of the article.

ACKNOWLEDGEMENTS

The authors thank the technical staff of the HLA and histocompatibility laboratory of Nancy for their expertise, and especially Sandra Clément for her help in data analysis. The authors are also grateful to Omixon Company for providing a free trial of their technology and to Mathieu Dewez for the technical support.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data supporting the findings of this paper are available upon request from the corresponding author.

ORCID

Adèle Dhuyser  <https://orcid.org/0000-0001-9340-5549>

Maël Silva Rodriguez  <https://orcid.org/0009-0007-6191-7452>

REFERENCES

- Mosbrugger TL, Dinou A, Duke JL, et al. Utilizing nanopore sequencing technology for the rapid and comprehensive characterization of eleven HLA loci; addressing the need for deceased donor expedited HLA typing. *Hum Immunol.* 2020;81(8):413-422. doi:10.1016/j.humimm.2020.06.004
- Duquesnoy RJ, Marrari M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. *Hum Immunol.* 2002;63(5):353-363. doi:10.1016/s0198-8859(02)00381-6
- Duquesnoy RJ, Marrari M. Usefulness of the ElliPro epitope predictor program in defining the repertoire of HLA-ABC eplets. *Hum Immunol.* 2017;78(7-8):481-488. doi:10.1016/j.humimm.2017.03.005
- Menezes Teles e Oliveira D, Melo Santos de Serpa Brandão R, Claudio Demes da Mata Sousa L, et al. pHLA3D: an online database of predicted three-dimensional structures of HLA molecules. *Hum Immunol.* 2019;80(10):834-841. doi:10.1016/j.humimm.2019.06.009
- Barker DJ, Maccari G, Georgiou X, et al. The IPD-IMGT/HLA database. *Nucleic Acids Res.* 2023;51(D1):D1053-D1060. doi:10.1093/nar/gkac1011
- Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. *Tissue Antigens.* 2010;75(4):291-455. doi:10.1111/j.1399-0039.2010.01466.x

How to cite this article: Dhuyser A, Silva Rodriguez M, Morel T, Pérès M, Aarnink A. The novel *HLA-C*07:1058* allele characterised by two different sequencing-based typing techniques. *HLA.* 2023;102(4):536-538. doi:10.1111/tan.15142

Characterization of the novel *HLA-C*12:384* allele by sequencing-based typing

Marine Cargou¹  | Vincent Elsermans²  | Isabelle Top² |
 Elodie Wojciechowski^{1,3} | Jonathan Visentin^{1,2}

¹CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France

²Institut d'Immunologie-HLA, CHU de Lille, Lille, France

³CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux University, Bordeaux, France

Correspondence

Marine Cargou, Laboratoire d'Immunologie et Immunogénétique,

*HLA-C*12:384* differs from *HLA-C*12:03:01:02* by one nucleotide substitution in codon 42 in exon 2.

CHU de Bordeaux, Hôpital Pellegrin,
Place Amélie Raba Léon, 33076 Bordeaux
Cedex, France.
Email: marine.cargou@chu-bordeaux.fr

KEYWORDS

HLA, *HLA-C*12:384*, novel allele, sequencing-based typing

We report here a novel *HLA-C*12* allele, now named *HLA-C*12:384* that carries one nucleotide substitution in exon 2 when compared to the *HLA-C*12:03:01:02* allele, identified in a volunteer bone marrow donor. The HLA typing was performed using Next Generation Sequencing (AllType NGS, One Lambda, Canoga Park, CA) on the Ion S5 system platform (ThermoFisher Scientific, Waltham, MA),¹ from exons 1 to 8. The reads were analyzed using the TypeStream Visual Software version 3.0 (One Lambda). This donor was found to have a new *C*12* allele and was consequently typed *A*29:02, 31:01; C*08:02, 12:384; B*35:08, 44:03; DRB1*07:01, 13:01; DRB3*01:01; DRB4*01:01P; DQA1*01:03, 02:01; DQB1*02:02, 06:03; DPA1*01:03, 02:01; DPB1*04:01, 10:01*. Using the IPD-IMGT/HLA Database,² nucleotide sequence alignment with HLA-C alleles shows that this new allele has one nucleotide change from *C*12:03:01:02* in codon 42 in exon 2, where G → A, resulting in a coding change (AGT → AAT, Serine → Asparagine, Figure 1). This nucleotide change was confirmed using other NGS reagents provided by GenDX NGSgo-MX6-1 (Utrecht, Netherlands) run on the Illumina MiSeq system (San Diego, CA) and analyzed with the NGS Engine software (GenDX, version 2.26). We were confident in the phasing as the sample displayed a mean read length of 339 base pairs over all the loci, the mismatched A base was attributed 198 times to the new *HLA-C*12* allele and can be only attributed to this allele because it was possible to discriminate from

the associated *HLA-C*08:02:01:05* allele by virtue of two variant positions each distant by less than 100 base pairs. HLA typing by Luminex reverse sequence-specific oligonucleotide (SSO) was performed (One Lambda Labtype XR, Canoga Park, CA).³ With this assay (lot 02A, catalog RSSOX1C_02A_03), the most likely HLA-typing of the donor was *C*08:DWJJA, 12:03:36* without any bead modification. We had to modify the bead #004 from positive to negative to obtain a *HLA-C*12:03:01* result. Indeed the bead #004 displayed oligonucleotides targeting the sequence surrounding codon 42 and was indicated by the manufacturer as reactive for the *HLA-C*12:123* which has an AAT in codon 42. Indeed, the IPD-IMGT/HLA Database 3.52.0 release describes only a few other HLA-C alleles displaying an AAT sequence at codon 42. The analysis of the localization of this amino-acid and its antibody accessibility with the pHLA3D database⁴ indicated that this amino-acid is located into the peptide binding groove. As such this could have an importance in both allogeneic hematopoietic stem cell transplantation and solid organ transplantation. The coding nucleotide sequence of the new allele has been submitted to the GenBank database (Accession No. OQ606806) and to the IPD-IMGT/HLA Database (Submission No. HWS10065701). The name *C*12:384* has been officially assigned by the WHO Nomenclature Committee for Factors of the HLA System in March 2023. This follows the agreed policy that,

AA Codon		5		10		15		20		25																				
<i>C*12:03:01:02</i>		GC	TCC	CAC	TCC	ATG	AGG	TAT	TTC	TAC	ACC	GCC	GTG	TCC	CGG	CCC	GGC	CGC	GGA	GAG	CCC	CGC	TTC	ATC	GCA	GTG				
<i>C*12:123</i>																														
<i>C*12:384</i>																														
AA Codon				30				35						40						45						50				
<i>C*12:03:01:02</i>				GGC	TAC	GTG	GAC	GAC	ACG	CAG	TTC	GTG	CGG	TTC	GAC	AGC	GAC	GCC	GCG	AGT	CCA	AGA	GGG	GAG	CCG	CGG	GCG	CCG		
<i>C*12:123</i>																														
<i>C*12:384</i>																														
AA Codon						55				60						65								70			75			
<i>C*12:03:01:02</i>						TGG	GTG	GAG	CAG	GAG	GGG	CCG	GAG	TAT	TGG	GAC	CGG	GAG	ACA	CAG	AAG	TAC	AAG	CGC	CAG	GCA	CAG	GCT	GAC	CGA
<i>C*12:123</i>																														
<i>C*12:384</i>																														
AA Codon								80					85																	
<i>C*12:03:01:02</i>								GTG	AGC	CTG	CGG	AAC	CTG	CGC	GGC	TAC	TAC	AAC	CAG	AGC	GAG	GCC	G							
<i>C*12:123</i>																														
<i>C*12:384</i>																														

FIGURE 1 Alignment of sequences of exon 2 of *HLA-C*12:384* and *C*12:123* with the sequence of *C*12:03:01:02*. Dashes indicate nucleotide identity with the *HLA-C*12:03:01:02* allele. Numbers above the sequence indicate codon position.

subject to the conditions stated in the most recent Nomenclature Report,⁵ names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report.

AUTHOR CONTRIBUTIONS

Marine Cargou and Jonathan Visentin contributed to the design of the study. Marine Cargou and Jonathan Visentin participated in the writing of the paper. Marine Cargou, Vincent Elsermans, Isabelle Top, Elodie Wojciechowski and Jonathan Visentin participated in the performance of the research. Marine Cargou, Vincent Elsermans, Isabelle Top, Elodie Wojciechowski and Jonathan Visentin participated in data analysis. Vincent Elsermans, Isabelle Top and Elodie Wojciechowski were involved in critical revision of the manuscript.

ACKNOWLEDGMENTS

The authors thank the technicians of the Bordeaux and Lille Immunology laboratories for their technical expertise.

CONFLICT OF INTEREST STATEMENT


The authors confirm that there are no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. The sequence is freely available in the IPD-IMGT/HLA Database.

ORCID

Marine Cargou  <https://orcid.org/0000-0002-1141-1417>




Vincent Elsermans  <https://orcid.org/0000-0002-0881-0695>

REFERENCES

1. Cargou M, Ralazamahaleo M, Blouin L, et al. Evaluation of the AllType kit for HLA typing using the ion torrent S5 XL platform. *HLA*. 2020;95(1):30-39. doi:10.1111/tan.13708
2. Barker DJ, Maccari G, Georgiou X, et al. The IPD-IMGT/HLA database. *Nucleic Acids Res*. 2023;51(D1):D1053-D1060. doi:10.1093/nar/gkac1011
3. Cargou M, Ralazamahaleo M, Blouin L, Guidicelli G, Visentin J. Improvement in HLA-C typing by a new sequence-specific oligonucleotides kit. *HLA*. 2020;96(3):323-328. doi:10.1111/tan.13986
4. Teles E, Oliveira DM, Marroquim MSC, de Serpa Brandão RMS, et al. pHLA3D: updating the database of predicted three-dimensional structures of HLA with HLA-DR, HLA-DQ and HLA-DP molecules. *Hum Immunol*. 2021;82(1):8-10. doi:10.1016/j.humimm.2020.10.007
5. Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. *Tissue Antigens*. 2010;75(4):291-455. doi:10.1111/j.1399-0039.2010.01466.x

How to cite this article: Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel *HLA-C*12:384* allele by sequencing-based typing. *HLA*. 2023;102(4):538-540. doi:10.1111/tan.15143

The new *HLA-DQB1*05:304* allele identified in an Italian patient

M. Troiano¹  | P. Giustiniani¹  | R. M. Pinto² | A. Di Luzio¹ | M. Andreani¹ 

¹Department of Oncohematology and Cell and Gene Therapy, Laboratory of Immunogenetics of Transplant, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy

²Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy

Correspondence

M. Troiano, Dipartimento di Oncoematologia e Terapia Cellulare e Genica, Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Viale Ferdinando Baldelli, 40-00146 Rome, Italy.
Email: maria.troiano@opbg.net

*DQB1*05:304* allele was identical to *DQB1*05:02:01* except for a single nucleotide substitution.

KEYWORDS

*HLA-DQB1*05* new, new allele, next generation sequencing